With the advent of Direct Acting Antivirals, treatment of hepatitis C during pregnancy may come into reach. In a recent publication in American Journal of Obstetrics and Gynecology researchers from the Departments of Pharmacology and Toxicology, Pharmacy, Obstetrics and Gynecology, Gastroenterology and Hepatology, investigated the placental passage of two such drugs for the first time.
Jolien Freriksen and colleagues from RIMLS and RIHS studied the placental passage of daclatasvir and the main circulating metabolite of the drug sofosbuvir (GS-331007). In the laboratory-based study, fetal and maternal circulations of term human placentas were re-established immediately after birth. In this controlled setting, it was then studied how the placenta handled the drugs, ex vivo.
A main finding of the study was that GS-331007 and daclatasvir both cross the human placental barrier. This indicates that maternal use of sofosbuvir/daclatasvir may be beneficial in terms of fetal pre-exposure prophylaxis, but on the other hand could have adverse fetal effects. For a better and safer treatment of women living with HCV, future studies should now further chart the potential of Direct Acting Antivirals to improve maternal health and reduce the prevalence of pediatric hepatitis C.
Related news items
Technology saves lives! 1.9 million euros from the Heart Foundation for developing smart watches17 November 2021
Niels van Royen is proud to be part of this consortium, initiated by Judith Bonnes, to develop a wrist band for early detection of cardiac arrest. Together with Erasmus, Reinier de Graaf and Corsano Health.read more
Turbo Grants for four medical-technical research projects19 October 2021
Four TURBO grants were recently awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between the University of Twente (TechMed Centre) and the Radboudumc.read more
COVID-19 associated coagulopathy - lessons after 1 year17 May 2021
Jenneke Leentjens, Saskia Middeldorp, and colleagues, published a review on the current knowledge of COVID-19 associated coagulopathy and the role of antithrombotic therapies in the Lancet Haematology.read more
Report of the 12th New Frontiers symposium Better care, network care? - 2 November 20187 November 2018
No easy answers at this symposium last Friday, only challenges that can be overcome if we succeed in 5 things. First and most radically, put patients in the center of healthcare. Second, start with assessing what the local population needs and not what local professionals have to offer.read more